The International AIDS Vaccine Initiative (IAVI), a nonprofit scientific research organisation, reports that its first human trial of a single-dose Lassa fever vaccine is safe, induces durable immunity, and supports Phase 2 trials in West Africa.
The single dose elicited robust and long-lasting immune responses while demonstrating an acceptable safety profile, according to findings published Thursday in the New England Journal of Medicine.
The News Agency of Nigeria (NAN)…
Read the full article here
